Signaling Pathways In Squamous Cancer

Squamous epithelia form the lining surface of tissues in contact with the environment: the skin, oral mucosa, esophagus and respiratory tract, the genital tract, and several other specialized tissues. These tissues are at highest risk for exposure to environmental carcinogens such as UV, tobacco smoke and infectious agents. Cancers that form in squamous epithelia are among the most common human solid tumors and have high morbidity and mortality. These cancers include squamous cell carcinoma of the skin, oral cancer, head and neck and esophageal cancer, certain lung cancers and cervical cancer. We propose to organize the book so that the early chapters will focus on individual pathways and more specific mechanisms in both normal function and cancer, while the later chapters will be more integrative and include overviews of biomarkers and therapeutic development. This should increase interest for clinically oriented researchers. All authors will be encouraged to provide a balanced review in addition to highlighting their own work.

Squamous epithelia form the lining surface of tissues in contact with the environment: the skin, oral mucosa, esophagus and respiratory tract, the genital tract, and several other specialized tissues. These tissues are at highest risk for exposure to environmental carcinogens such as UV, tobacco smoke and infectious agents. Cancers that form in squamous epithelia are among the most common human solid tumors and have high morbidity and mortality. These cancers include squamous cell carcinoma of the skin, oral cancer, head and neck and esophageal cancer, certain lung cancers and cervical cancer. We propose to organize the book so that the early chapters will focus on individual pathways and more specific mechanisms in both normal function and cancer, while the later chapters will be more integrative and include overviews of biomarkers and therapeutic development. This should increase interest for clinically oriented researchers. All authors will be encouraged to provide a balanced review in addition to highlighting their own work.

One of the most exciting areas of cancer research now is the development of agents which can target signal transduction pathways that are activated inappropriately in malignant cells. The understanding of the molecular abnormalities which distinguish malignant cells from their normal counterparts has grown tremendously. This volume summarizes the current research on the role that signal transduction pathways play in the pathogenesis of cancer and how this knowledge may be used to develop the next generation of more effective and less toxic anticancer agents. Series Editor comments: "The biologic behavior of both normal and cancer cells is determined by critical signal transduction pathways. This text provides a comprehensive review of the field. Leading investigators discuss key molecules that may prove to be important diagnostic and/or therapeutic targets."

This thoroughly revised second edition is an up-to-date overview of the current knowledge of Notch and Notch signaling in embryology and cancer. It discusses this topic from Notch’s role in the development of the embryo to the Notch signaling pathway’s role in the development of a number of cancers, including breast cancer, malignant melanoma, Non-melanoma skin cancer, intestinal cancer and others. In the years since the previous edition, there have been numerous developments and insights within this rapidly moving field, making this new edition urgently needed. This volume also features discussions of current insights on Notch’s role in senescence, the regulation of Notch signaling by microRNAs, Notch’s role in the microbiome, diet and its influence on Notch signaling and more. Taken as a whole, with its companion books -- Notch Signaling and Embryologic Development and Molecular Basis of Notch Signaling – this is a definitive discussion of the topic, presented by internationally-recognized contributors. Presented in a coherent and accessible structure, this revised and updated second edition is an essential and up-to-date guide for oncologists, embryologists, researchers and advanced students.

In the past decade, we have experienced an explosion of new information about cancer therapeutic targets. Many of the targets have been validated by the discovery and approval of new medicines which have been approved for the treatment of cancer. On the heels of these successes, innumerable new targets and new potential therapeutics are being developed by many different groups including government agencies, pharmaceutical companies, biotechnology companies, academic institutions, and individual investigators. Understanding the expanding "universe" of cancer therapies is therefore becoming impossible and no single source exists which serves as a reference for the involved parties. Further, the interested parties have vastly different areas of expertise, from focused laboratory based science, to clinical research, to corporate and regulatory oversight. The text would be updated every two years, more often depending on pace of change, interest and sales. While useful online, this reference book would likely be kept in hard copy as well.

With the support of multinational specialists, each with different background and separate field of expertise in oncology, this book had the occasion to emerge and to offer physicians, researchers and academics efficient, well-organized and updated scientific information related to the characteristics and treatment modalities of squamous cell carcinoma. It provided in-depth information regarding the comprehension of the molecular interaction of signalling pathways and new phenotypes that might result and lead to further cell proliferation and metastases. It also emphasized on the management and individualization of treatment strategies in different types of SCC, applying molecular profiling and approved protocols in order to identify new treatment opportunities. This book also discussed the potential therapeutic modalities that might arise upon understanding and exploring the role of key regulatory proteins that govern the process of cutaneous SCC progression. And Lastly, it underlined the molecular aberrations present in SCC of different organs and the possibility of emerging new therapeutic drugs by targeting these abnormalities. It is really an innovative record that combined novel information from various medical sources and mixed it to become unified in its scientific profit.

Cells respond to environmental cues through a complex and dynamic network of signaling pathways that normally maintain a critical balance between cellular proliferation, differentiation, senescence, and death. One current research challenge is to identify those aberrations in signal transd- tion that directly contribute to a loss of this division-limited equilibrium and the progression to malignant transformation. The study of cell-signaling m- ecules in this context is a central component of cancer research. From the knowledge of such targets, investigators have been able to productively advance many insightful hypotheses about how a particular cancer cell may misinterpret, or respond inappropriately to, growth regulatory cues in their environment. Despite these key insights, the rapidly evolving nature of cell signaling research in cancer has necessitated a continuous revision of these theoretical constructs and the updating of methods used in their study. One contemporary example of the evolution of this field is provided by an analysis of the Human Genome Project data, which reveal a previously unsuspected diversity in the multigene families encoding for most signaling pathway int- mediates. In assessing the usefulness of a particular methodological approach, therefore, we will need to keep in mind that there is a premium on those p- tocols that can be easily adapted for the analysis of multiple members within a gene family. Cancer Cell Signaling: Methods and Protocols brings together several such methods in cell signaling research that are scientifically grounded within the cancer biology field.

Human skin cancers, the most common type of tumors, represent a significant health burden. The deadliest is unquestionably melanoma. Half of melanomas have an activating mutation in the BRAF gene, prompting development of novel drugs, vemurafenib and dabrafenib, specifically targeting mutated BRAF. Trametinib and cobimetinib, which block MEK, a BRAF effector protein, have been used in combination with BRAF inhibitors. A promising new melanoma treatment is immunotherapy, approach that boosts patient's own immune system to attack cancer. Pembrolizumab and nivolumab inhibit PD-1, whereas Ipilimumab targets CTLA-4, another immunity check point, to boost the immune response. Here we focus on pathways, mechanisms, targets and treatments of human skin cancers, with particular emphasis on the new developments in the research on melanomas.